Skip to Content
Merck
All Photos(1)

Documents

MAB3070

Sigma-Aldrich

Anti-Granzyme B Antibody, clone GrB-7

culture supernatant, clone GrB-7, Chemicon®

Synonym(s):

Anti-Anti-C11, Anti-Anti-CCPI, Anti-Anti-CGL-1, Anti-Anti-CGL1, Anti-Anti-CSP-B, Anti-Anti-CSPB, Anti-Anti-CTLA1, Anti-Anti-CTSGL1, Anti-Anti-HLP, Anti-Anti-SECT

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

culture supernatant

antibody product type

primary antibodies

clone

GrB-7, monoclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

immunohistochemistry: suitable (paraffin)
western blot: suitable

isotype

IgG2a

NCBI accession no.

UniProt accession no.

shipped in

dry ice

target post-translational modification

unmodified

Gene Information

human ... GZMB(3002)

Specificity

Monoclonal antibody recognizes the 33 kDa granzyme B.

Reacts specifically with human serine protease granzyme B. Does not cross-react with human granzyme A. Granzyme B localizes in cytoplasmic granules and can be used as a marker for NK cells and activated cytotoxic T-cells.

Application

Detect Granzyme B using this Anti-Granzyme B Antibody, clone GrB-7 validated for use in WB, IH(P).
Immunoblotting

Immunohistochemistry of granzyme B-expressing lymphocytes in sublimate sections and formalin-fixed paraffin-embedded tissues (1:20 dilution). Does not react with other cell types. Cannot be used on frozen sections.

Note on the use of MAB3070 on paraffin sections:

Tissue slides should be pretreated with an antigen retrieval method, such as treatment with 0.1M sodium citrate for 10 min at 100°C. A working dilution of 1:20 is advised, but optimal working dilutions must be determined by end user.
Research Category
Apoptosis & Cancer

Metabolism
Research Sub Category
Apoptosis - Additional

Enzymes & Biochemistry

Physical form

Liquid

Storage and Stability

Maintain at -20°C for up to 12 months.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 2


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Milan Fiala et al.
Journal of neuroinflammation, 7, 76-76 (2010-11-11)
The contribution of inflammation to neurodegenerative diseases is increasingly recognized, but the role of inflammation in sporadic amyotrophic lateral sclerosis (sALS) is not well understood and no animal model is available. We used enzyme-linked immunosorbent assays (ELISAs) to measure the
Jenny Bulgarelli et al.
Frontiers in immunology, 10, 2353-2353 (2019-10-28)
Dendritic cell (DC)-based vaccination effectively induces anti-tumor immunity, although in the majority of cases this does not translate into a durable clinical response. However, DC vaccination is characterized by a robust safety profile, making this treatment a potential candidate for
Shintaro Yokoyama et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 22(18), 4727-4734 (2016-05-12)
The immune checkpoint of the programmed death 1/programmed death ligand 1 (PD-1/PD-L1) pathway is believed to play an important role in evasion of host antitumor immune surveillance in various malignancies; however, little is known about its role in thymic carcinoma.
Mingyao Meng et al.
The Journal of biological chemistry, 293(51), 19600-19612 (2018-10-20)
Several clinical immunotherapy trials with cytokine-induced killer (CIK) cells have been reported. However, molecular evidence of cell expansion, acquisition of tumor cytotoxicity, and safety of CIK cells is required before putting them to clinical use. Here, we performed dynamic transcriptomic
Yong Zeng et al.
Molecular therapy. Methods & clinical development, 18, 422-427 (2020-07-23)
Intravitreal administration for human adeno-associated vector (AAV) delivery is easier and less traumatic to ocular tissues than subretinal injection, but it gives limited retinal transduction. AAV vectors are large (about 4,000 kDa) compared with most intraocular drugs, such as ranibizumab (48 kDa)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service